Merck, Ridgeback to supply 3 million courses of molnupiravir

Tuesday, 18. January 2022 13:12

Merck and Ridgeback Biotherapeutics will sign a "long-term supply agreement" with the United Nations Children’s Fund (UNICEF) to ensure global access to molnupiravir, the COVID-19 oral drug.

According to a press note released by Merck, they will allocate a total of 3 million courses of molnupiravir "for distribution in more than 100 low- and middle-income countries following regulatory authorizations".

"Merck is delivering on our commitment to make molnupiravir available – widely, quickly, and equitably. Through this groundbreaking agreement with UNICEF, millions of patients in more than 100 low- and middle-income countries will gain access to molnupiravir through UNICEF and the ACT Accelerator Therapeutics Partnership in the first half of 2022," stated Robert M. Davis, chief executive officer and president.

Related Links: Merck & Co. Inc.
Author:
Baha Breaking News (BBN) / JG